AVEOA
Avecho Biotechnology Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Avecho Biotechnology Limited - Option Expiring 10-May-2026
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.00
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in AVEOA
1
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in AVEOA
N/A
AVEOA investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
100%
πΆ Age of investors
18 - 25
26 - 34
35 - 90
100%
π Legal gender of investors
Female
100%
Male
Pearlers who invest in AVEOA also invest in...
APA
APA Group engages in the business of owning, managing, and operating diverse portfolios of gas, electricity, solar, and wind assets. The company is headquartered in Sydney, New South Wales. The company went IPO on 2000-06-13. The firm owns and/or manages and operates a portfolio of gas, electricity, solar and wind assets. Its segments include energy infrastructure, asset management and energy investments. The firm owns energy infrastructure assets across gas transmission, compression, processing, storage and electricity generation (gas and renewables) and transmission. The asset management segment includes the provision of asset management and operating services for third parties and the majority of the Company's energy investments. The energy investments segment includes interests in energy infrastructure investments. The company also owns and operates renewable power generation assets in Australia, with wind and solar projects across the country. Its gas storage facilities include Mondarra Gas Storage and Processing Facility, and Dandenong LNG Gas Storage Facility.
π Performance (5Yr p.a)
-7.53%
π Share price
$7.23 AUD
π UTILITIES
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 207 full-time employees. The company went IPO on 2012-03-18. The firm is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
π Performance (5Yr p.a)
100.95%
π Share price
$3.81 AUD
𧬠BIOTECHNOLOGY
Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. The company is headquartered in Melbourne, Victoria. The firm develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The firm's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The firm's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The firm is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
π Performance (5Yr p.a)
-2.86%
π Share price
$0.00 AUD
π¦ LOGISTICS
Lark Distilling Co. Ltd. engages in the production, marketing, sale, and distribution of Australian craft spirits. The company is headquartered in Hobart, Tasmania. The company went IPO on 2003-11-12. The firm has three segments: whisky, gin, and other. The company offers various Whisky products, such as Dark Lark Single Malt Whisky, Classic Cask, Boilermaker House Whisky Bar Limited Release, and Para 1992 Cask Finish with 100ml Tawny Liqueur, among others. The company offers a range of Gin products, which include Forty Spotted Citrus & Pepperberry + Pinot Noir Gin, Forty Spotted Classic Gin & Raspberry + Rose, Forty Spotted Classic, Forty Spotted Tassie Bush Honey, Forty Spotted Wild Rose, Forty Spotted Citrus & Pepperberry, Forty Spotted Raspberry & Rose, and Forty Spotted Pinot Noir. The company operates in Tasmania and Australia. The company markets its products via traditional off-premise retailers and on-premises bars, and via its direct-to-consumer business, which is hospitality and online e-commerce. Its primary focus is Whisky and the Lark brand.
π Performance (5Yr p.a)
2.42%
π Share price
$1.11 AUD
π FOOD PRODUCTS
VESG.AX was created on 2018-09-11 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious International Shares Index ETF seeks to track the return of the FTSE Developed ex Australia Choice Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax
π Performance (5Yr p.a)
15.45%
π Share price
$101.94 AUD
π€ TECHNOLOGY
β³οΈ DIVERSIFIED
π GLOBAL
π HIGH PRICE GROWTH
Want more shares? Try these...
Australian Vintage Ltd. engages in wine making, wine marketing, and vineyard management. The company is headquartered in Adelaide, South Australia. The Companyβs principal activities include wine making, wine marketing, and vineyard management. Its segments include Australia / New Zealand, UK, Europe & Americas, and Asia. Australia / New Zealand segment is engaged in the growing of grapes, manufacturing, sales and marketing of alcoholic wine, non-alcoholic wine and other beverages in Australia, New Zealand and the Pacific through wholesale and retail channels. In addition, the Australia / New Zealand segment sells concentrate and other commercial products to customers globally. UK, Europe & Americas segment is engaged in the packaging, sales and marketing of alcoholic wine, non-alcoholic wine and other beverages in the United Kingdom, Europe & the Americas through wholesale, distributor and retail channels. Asia segment is engaged in the sales and marketing of alcoholic wine, non-alcoholic wine and other beverages in Asia through wholesale channels.
π Performance (5Yr p.a)
-14.57%
π Share price
$0.14 AUD
π FOOD PRODUCTS
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 207 full-time employees. The company went IPO on 2012-03-18. The firm is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
π Performance (5Yr p.a)
100.95%
π Share price
$3.81 AUD
𧬠BIOTECHNOLOGY
AVADA Group Ltd. engages in the provision of traffic management and ancillary services. The company is headquartered in Brisbane, Queensland. The company went IPO on 2021-12-17. The firm operates through four segments: Queensland Traffic Management, New South Wales Traffic Management, Victoria Traffic Management, and New Zealand Traffic Management. Queensland Traffic Management contains entities which operate in the Queensland geography. New South Wales Traffic Management contains entities which operate in the New South Wales geography. Victoria Traffic Management contains entities which operate in the Victorian geography. New Zealand Traffic Management contains entities which operate in the New Zealand geography. Its businesses include Verifact Traffic, A2O Traffic Solutions, D&D Traffic Management, Platinum Traffic Services, Traffic Marshal, Construct Traffic, TRAFFIC MANAGEMENT PEOPLE (TMP) and Linemark Traffic Control.
π Share price
$0.48 AUD
π¨ COMMERCIAL SERVICES & SUPPLIES
Avecho Biotechnology Ltd. engages in the development and commercialization of human and animal products through its proprietary drug delivery system. The company is headquartered in Melbourne, Victoria. The firm develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The firm's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The firm's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The firm is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
π Performance (5Yr p.a)
-2.86%
π Share price
$0.00 AUD
π¦ LOGISTICS